Replies to post #114634 on Biotech Values

[jackrmormon]

MNTA's top six FOB targets:

Don't know the patent expiries but have to believe an RA FOB is inevitable. Then Rituxan?

[biomaven0]

Interesting that Nexium (number 2 last year) has dropped completely out of the top 10. Insurance company muscle finally having some impact (forcing switches to comparable generics).

Here's data for the top 100 for the last few years:

http://cbc.arizona.edu/njardarson/group/top-pharmaceuticals-poster

Peter